Seattle Genetics, Inc. SGEN announced today that it will receive
undisclosed milestone payments under its antibody-drug conjugate (ADC)
collaboration with Genentech, a member of the Roche Group RO ROG
RHHBY. The milestones were triggered by Genentech's advancement of two
ADCs utilizing Seattle Genetics technology into phase II clinical development.
The phase II randomized, open-label study is designed to evaluate the safety
and efficacy of ADCs anti-CD22 (DCDT2980S, RG7593) and DCDS4501A (RG7596) each
in combination with Rituxan® (rituximab) in patients with relapsed or
refractory follicular non-Hodgkin lymphoma and relapsed or refractory diffuse
large B-cell lymphoma.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in